Drugs / TORL-2-307-MAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05159440 | Jan 2022 → Dec 2024 overdue | gastric cancer, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm | TORL Biotherapeutics, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TORL-2-307-MAB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05159440 ↗ |
| Target | CLDN18 | “targeting CLDN18.2” PMID 37788341 ↗ Dec 2023 |